💉 Research stack weight loss

The Metabolic Stack

Retatrutide targets fat loss through triple receptor agonism — GLP-1, GIP and glucagon simultaneously. AOD 9604 approaches fat metabolism through a completely different mechanism — beta-3 adrenergic receptor activation — without affecting growth hormone pathways. Together they cover more of the metabolic landscape than either alone.

💉 Retatrutide 🩹 AOD 9604
What this stack is studied for
  • Triple GLP-1/GIP/glucagon receptor activation
  • Direct fat cell lipolysis via beta-3 adrenergic receptors
  • Complementary weight loss mechanisms
  • No IGF-1 elevation from AOD 9604
  • Next-generation metabolic research combination
Retatrutide GLP-1
AOD 9604 Research peptide
COA Purity certified vendors only
5 Markets covered

What is The Metabolic Stack?

Retatrutide + AOD 9604 — why combine them?

The Metabolic Stack combines two compounds with distinct fat metabolism mechanisms. Retatrutide (LY3437943) is Eli Lilly's triple GLP-1/GIP/glucagon agonist currently in Phase 3 trials, showing up to 24% body weight reduction in Phase 2 data. AOD 9604 is a modified fragment of human growth hormone (amino acids 176-191) developed at Monash University in Australia.

The key distinction is mechanism — retatrutide primarily reduces appetite and improves metabolic function through central and peripheral GLP-1/GIP/glucagon receptor activation. AOD 9604 stimulates lipolysis directly through beta-3 adrenergic receptors without IGF-1 elevation or anabolic effects.

Why combine them?

Retatrutide works centrally and peripherally via GLP-1/GIP/glucagon receptors — reducing appetite, improving insulin sensitivity, and increasing energy expenditure. AOD 9604 works peripherally at fat cells via beta-3 adrenergic receptors — directly stimulating lipolysis. They target fat loss through completely different mechanisms.

Plain English

What this means for you

If you are researching compounds for weight loss and metabolic health, this stack combines the most promising next-generation GLP-1 compound with one of the most targeted fat metabolism peptides in the research literature.

Retatrutide is the heavy hitter — the compound showing the strongest weight loss data of any GLP-1 class molecule in Phase 2 trials. AOD 9604 adds a direct fat-burning mechanism on top, without the growth-promoting side effects of full growth hormone.

Think of retatrutide as working on your appetite and metabolism from the inside out, while AOD 9604 goes directly after stored fat through a separate pathway.

The compounds

What's in this stack

Retatrutide💉
Retatrutide
Triple GLP-1/GIP/glucagon receptor agonist — next-generation metabolic research compound
Reported benefits
Significant body weight reduction in clinical trials
Improved blood glucose and insulin sensitivity
Reduced appetite via central GLP-1 mechanisms
Increased energy expenditure via glucagon receptor activation
Full Retatrutide research guide →
AOD 9604🩹
AOD 9604
Modified GH fragment studied for fat metabolism without the growth-promoting effects of full GH
Reported benefits
Stimulates fat breakdown via beta-3 adrenergic pathway
No IGF-1 elevation — does not promote tissue growth
GRAS status from FDA for food ingredient use
Australian-origin research compound (Monash University)
Full AOD 9604 research guide →

Why they work together

Complementary mechanisms

01
Complementary mechanisms
Retatrutide reduces appetite and improves metabolic rate via GLP-1/GIP/glucagon receptors. AOD 9604 directly stimulates lipolysis via beta-3 adrenergic receptors. No pathway overlap — pure complementarity.
02
No IGF-1 interference
AOD 9604 does not raise IGF-1 or stimulate the growth axis, unlike full-length growth hormone. This means it can be combined with GLP-1 peptides without concerns about anabolic interference.
03
Phase 3 + established research
Retatrutide brings the strongest Phase 2 weight loss data of any GLP-1 compound. AOD 9604 has Phase 2 human trial data and Australian research backing spanning decades.

Source this stack

Where are you based?

Select your market to see COA-verified vendors for both compounds. We only list vendors with third-party purity certification.

🇦🇺 Australia — TGA
✓ Legal for research Both compounds unscheduled under TGA. AOD 9604 was developed in Australia. Legal for research.
💉 Retatrutide COA verified

Available from verified vendors. Click to view options for your selected market.

View Retatrutide vendors →
🩹 AOD 9604 COA verified

Available from verified vendors. Click to view options for your selected market.

View AOD 9604 vendors →